Summary
Population pharmacokinetic analysis of the anticancer agent epirubicin was carried out using the program NONMEM. Data were available from 36 patients aged 20–73 years, of whom 23 were women. All subjects exhibited normal liver and renal function. Epirubicin was given as a short-term i. v. infusion over the dose range of 25–100 mg/m2, and an average of 11 plasma samples/subject were taken for a period of up to 72 h after each dose. A Two compartment model was fitted to the data, characterised by the parameters clearance, volume of the central compartment, alpha and beta. Clearance was tested as a linear function of various demographic and/or biochemical features. A significant proportion of the variability in clearance could be attributed to sex, and also to age in women. For example, a 25-year-old man would display an average clearance of 95 l/h, whereas a 70-year-old woman would exhibit an average clerance of 64 l/h. Such differences in clearance might be important in the selection of epirubicin dose regimens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beal SL, Sheiner LB (1979, 1989) NONMEM (user's guide), parts I–VI. Technical report. Division of Clinical Pharmacology, University of California, San Francisco
Camaggi CM, Strocchi E, Tamassia V, Martoni A, Giovannini M, Iafelice G, Canova N, Marraro D, Martini A, Pannuti F (1982) Pharmacokinetic studies of 4′-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep 66:1819–1824
Cersosimo RJ, Hong WK (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an Adriamycin analogue. J Clin Oncol 4:425–439
Eksborg S (1989) Pharmacokinetics of anthracyclines. Acta Oncol 28:873–876
Evans WE, Relling MV (1989) Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 16: 327–336
Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman P, George SL, Pui C-H (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med 314:417–477
Hartman N, Basseches PJ, Powis G (1982) Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of Adriamycin metabolites in the rat. Cancer Chemother Pharmacol 10:11
Hu OY-P, Chang S-P, Jame J-M, Chen K-Y (1989) Pharmacokinetic and pharmacodynamic studies with 4′-epi-doxorubicin in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 24: 332–337
Israel M, Pegg WJ, Wilkinson PM, Garnick MB (1978) Liquid chromatographic analysis of Adriamycin and metabolites in biological fluids. J Liquid Chromatogr 1:795–809
Milano G, Namer M, Boublil J-L, Khater R, Frenay M, Thyss A, Bourry J, Philip C, Renee N, Bruneton J-N (1987) Relationship between systemic 5-FU passage and response in colorectal patients treated with interhepatic chemotherapy. Cancer Chemother Pharmacol 20:71–74
Natale N, Piazza E, Italia C, Trabattoni A, Luchini S (1983) The kinetics of anthracyclines in human plasma and tissues: daunomycin, doxorubicin and 4′-epidoxorubicin. Drugs Exp Clin Res IX: 775–779
Powis G (1985) Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14:177–183
Robert J (1980) Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liquid Chromatogr 3:1561–1572
Robert J, Vrignaud P, Nguyen-Ngoc T, Iliadis A, Mauriac L, Hurteloup P (1985) Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 69:633–640
Rodman JH, Abromowitch M, Sinkule JA, Hayes A, Rivera GK, Evans WE (1987) Clinical pharmacodynamics of continuous infusion teniposide — systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 5:1007–1014
Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics from routine clinical data. J Clin Oncol 5: 445–474
Tjuljandin SA, Doig RG, Sobol MM, Watson DM, Sheridan WP, Morstyn G, Mihaly G, Green MD (1990) Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res 50: 5095–5101
Vrignaud P, Eghball H, Hoerni B, Iliadis A, Robert J (1985) Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients. Eur J Cancer Clin Oncol 21: 1307–1315
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wade, J.R., Kelman, A.W., Kerr, D.J. et al. Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother. Pharmacol. 29, 391–395 (1992). https://doi.org/10.1007/BF00686009
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686009